Compare Hims and Hers Health Inc (HIMS) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs ING Groep NV — how do they compare? Hims and Hers Health Inc trades at $30.22 (market cap $6.55B), while ING Groep NV trades at $33.32 (market cap $93.76B). The key difference: ING Groep NV is far larger — about 14.3× Hims and Hers Health Inc's market cap, and ING Groep NV pays a 3.95% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and ING Groep NV for 94 Days on average.
| HIMS | ING | |
|---|---|---|
Market Cap | $6.55B | $93.76B |
Volume | 14,842,814 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $62.76 | $37.27 |
52-Week Low | $14.52 | $23.66 |
Typical Hold Time | 21 Days | 94 Days |
Enterprise Value | $7.25B | $236.48B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
ING stock trades at $33.28, down 1.89% today, with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains a 28.34% net income margin, and analysts show strong support with 11 buy ratings versus no sell ratings. Recent news highlights management's raised ROE target above 16% for 2027 and strategic focus on organic growth.
The investment case balances solid profitability and analyst optimism against technical weakness and cash flow challenges. Upside potential exists from earnings momentum and strategic initiatives, while risks include persistent negative operating cash flows and regulatory scrutiny in international markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
